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Background
The risk of neoplasis is increased in HIV-infected subjects.
Beside traditional determinants of cancer occurrence, a
specific role of HIV-related immunosuppression is
strongly suspected and a more complex relationship
between HIV and antiretroviral therapy (ART) cannot be
excluded. Our objective was to disentangle the relation-
ship between some frequently diagnosed cancers in HIV-
infected patients and immunosuppression, HIV and ART
exposure.
Methods
Patients from the ANRS CO3 Aquitaine Cohort were
included in this study if they had a duration of follow-up
of at least three months, at least two follow-up visits
recorded within the study period (1998 to 2006) and if
one HIV RNA plasma viral load (VL) was collected within
the first follow-up visit. Durations of exposure were calcu-
lated as the time durations with CD4 count <200 and 500
cells/mm3 or VL >500 copies/mL. Multivariate modelling
was based on extended Cox proportional hazards models
for time-time dependent covariates and delayed entry (at
time of first VL measurement). ART exposure was defined
as the prescription of at least three antiretroviral drugs.
Results
Among the 4,194 patients included, 61 cases of Non-
Hodgkin's lymphoma, 41 Kaposi's sarcoma, 41 bron-
chopulmonary and upper respiratory tract cancers, 20
skin cancers, 18 cases of Hodgkin's disease, 16 hepatocar-
cinomas and 14 anal cancers were reported during the
study period. Kaposi's sarcoma was independently associ-
ated with each year spent with CD4 <200 (Hazard ratio
[HR] = 1.53; 95% CI: 1.23 – 1.90; p < 0.001), each year of
ART exposure (HR = 0.74; 95% CI: 0.61 – 0.90; p < 0.003)
and male gender (HR = 5.26; 95% CI: 1.66 – 16.66; p <
0.006). Non-Hodgkin's lymphoma was associated with
each year spent with HIV RNA >500 (HR = 1.34; 95% CI:
1.19 – 1.51; p < 0.001), each year with CD4 <200 (HR =
1.31; 95% CI: 1.12 – 1.53; p < 0.001), and each year of
ART exposure (HR = 0.86; 95% CI: 0.75 – 0.99; p < 0.03).
Hepatocarcinoma was independently associated with
each year spent with CD4 <500 (HR = 1.31; 95% CI: 1.06
– 1.63; p = 0.012). Anal cancer was also independently
associated with each year spent with HIV RNA >500 cop-
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ies/mL (HR = 1.31; 95% CI: 1.02 – 1.68; p = 0.033).
Regarding the associations between skin, anal and bron-
chopulmonary cancers and CD4 <200, the adjusted anal-
yses showed p-values of 0.058, 0.112 and 0.13,
respectively).
Conclusion
Together with immunosuppression, HIV VL may be inde-
pendently associated with an increased risk of some can-
cers, AIDS-defining or not. Due to the limited statistical
power to investigate several types of cancers that are still
relatively infrequent, our results need to be confirmed by
further studies, possibly collaborative and including
lower-income country cohorts. Moreover, maintaining a
high CD4 count, a strict control of HIV VL with fully sup-
pressive ART could have a direct and measurable impact
in preventing the currently predictable increasing occur-
rence of cancer in HIV-infected patients, in addition to
other prevention policies.Page 2 of 2
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